Skip to main content
main-content

14-10-2020 | Gastroenterology | Video

UEGW 2020 | Ozanimod maintains remission in patients with ulcerative colitis

Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).

Funding for independent interviews at UEG Week Virtual 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits